The Psoriasis and Psoriatic Arthritis Research and Evaluation Group (GRAPPA) is dedicated to advancing clinical care, education, and research for patients with psoriasis and psoriatic arthritis. This multidisciplinary organization brings together rheumatologists, dermatologists, basic scientists, medical trainees, research trainees, and patient research partners.
The organization recently celebrated 20 years of supporting the development of medical guidelines for the treatment of psoriasis and psoriatic arthritis. GRAPPA also educates practitioners about new developments in the field and funds research grants to advance medical knowledge of psoriasis and psoriatic arthritis.
“GRAPPA was founded to bring together diverse expertise to explore ways to improve outcomes for affected patients by taking advantage of the many new treatments and therapeutic approaches for psoriatic arthritis and psoriasis. I did (and still do),” said Arthur Kavanaugh, MD. , professor of medicine at the University of California, San Diego. He continued, “Since its establishment, GRAPPA has [psoriatic arthritis], develop new research studies, support research and support educational programs. ”
GRAPPA’s goals include providing opportunities for clinicians to share knowledge and research results, facilitating the development of national and international collaborative patient registries to standardize data, and improving public awareness of psoriasis and psoriatic arthritis. This includes promoting. “We are excited to expand the types of research being conducted, including clinical, translational, and basic science research.” GRAPPA Research Committee Co-Chair Vinod Chandran, MD, PhD, Ph.D. No., MBBS, FRCPC Associate Professor, Department of Rheumatology, Faculty of Medicine, University of Toronto, and Director of the Psoriatic Arthritis Program, Schroeder Arthritis Institute, University Health Network. said Wilson Liao, MD, professor of dermatology and associate director of research at the University of California, San Francisco. Dermatology Times.
They further state that “topics of special interest include developing better methods to diagnose psoriatic arthritis, understanding the full spectrum of psoriatic disease, improving outcome measurement tools, and developing new molecular and digital biomarkers.” “These include identifying, understanding sex and gender differences, and considering best practices for addressing difficult diseases.” -To treat the patient. We are thrilled that many of these research efforts are supported by the collaborative efforts of academia, industry, nonprofit organizations, and patient research partners. ”
GRAPPA also collaborates with other professional organizations, such as the American Academy of Dermatology and the American College of Rheumatology, to advance research knowledge in these specialties. Additionally, the group works closely with representatives from member biopharmaceutical companies to conduct research on effective treatments and promote public awareness of psoriasis and psoriatic arthritis.
GRAPPA offers video training modules to support clinicians learning tests such as Psoriasis Area and Severity Index and Nail Psoriasis Severity Index. This nonprofit organization is based in Seattle, Washington and has more than 1,000 members from around the world.